-
Under the new policy of medical reform, pharmaceutical distribution enterprises have accelerated their transformation!
Time of Update: 2022-04-15
The company has stated that under a clear development strategy, around the goal of improving value to increase market value, standardize operations, adhere to the concept of "performance is king" and further promote enterprise transformation and innovation, continue to optimize business models and profitability, and improve.
-
Strong pharmaceutical demand drives the development of pharmaceutical machines, and many companies such as Canaan Technology have achieved gratifying performance
Time of Update: 2022-04-15
Regarding the changes in performance, Canaan Technology said that during the reporting period, the company continued to steadily improve the operational efficiency of various businesses, optimize the revenue structure, and coordinate the development of upstream and downstream businesses in the entire industry chain to ensure the company's oral solid preparation equipment, biological preparation fluid equipment and various businesses.
-
After the medical insurance of traditional Chinese medicine formula granules can be reimbursed, the market will accelerate the expansion
Time of Update: 2022-04-15
According to the "Notice", qualified Chinese medicine formula granules, after being reviewed by experts, will be included in the payment scope of the basic medical insurance fund of Fujian Province according to 70% of the sales price, and the limited payment scope of the corresponding Chinese medicine decoction pieces will be implemented with reference to the regulations .
-
10 boards in 12 days!
Time of Update: 2022-04-15
According to the 2021 third quarter report released by Panlong Pharmaceutical, the company achieved a total operating income of 623 million yuan in the first three quarters of 2021, a year-on-year increase of 37.
-
Pharmaceutical companies have embarked on the road of innovation, and these pain points may become "stumbling blocks"
Time of Update: 2022-04-15
According to the industry, the investment of large pharmaceutical companies in drug innovation has been increasing in recent years, but there are still very few new drugs that can enter the market every year, and the number of failed new drug R&D projects is still increasing day by day .
-
Strategy for the second quarter of 2022 in the pharmaceutical field: overall or relatively stable, investment still needs to be carefully selected
Time of Update: 2022-04-15
The agency predicts that according to the performance of Zhaoyan New Drug, the company's net profit in 2022-2023 is expected to be 730 million, 920 million, and 2022-2023 EPS will be 1.
-
The traditional Chinese medicine sector is active again, and stocks such as Longjin Pharmaceutical have opened their daily limit
Time of Update: 2022-04-15
The third quarterly report shows that in the first three quarters of 2021, the company's main income was 969 million yuan, a year-on-year increase of 4.
Shanghai Kaibao is a comprehensive pharmaceutical company mainly engaged in the R&D, production and sales of modern Chinese medicines .
-
The "water seller" collapsed!
Time of Update: 2022-03-09
S. Department of Commerce had a set of routine verification procedures for the reasonable use of these products (that is, for personal use, not for resale), but in the past two years due to the impact of the new crown pneumonia epidemic, it could not be completed in time, which led WuXi Biologics to enter the UVL .
-
"Rising" has become a hot word of the year, and these traditional Chinese medicine companies have received attention
Time of Update: 2022-03-09
Comments: The raw materials of traditional Chinese medicine have been put on the cloak of capital, and the price changes have largely been separated from their real value .
-
14 domestic class 1 new drugs are coming!
Time of Update: 2022-03-09
Sales of some ALK inhibitors in Chinese public medical institutions and physical pharmacies in Chinese cities in 2020 (unit: 10,000 yuan) Source: Minet database Innovative Drug One Brother, the first new drug introduced by Hengrui Medicine, known as "Innovative Drug One Brother" Hengrui Medicine, known as Hengrui Medicine, currently has 10 innovative drugs (9 category 1 new drugs) approved for marketing in China, of which anti-tumor drugs account for "half of the country" .
-
Burnet prices rose slightly, and the weak inventory pushed the market to continue to rise!
Time of Update: 2022-03-09
Years ago, there were not many supplies in the market, and the price fluctuated slightly, but the overall attention was not high .
-
The latest results of a group of pharmaceutical companies listed on the Science and Technology Innovation Board are announced
Time of Update: 2022-03-09
Among them, BeiGene, with a market value of 100 billion, has become the first listed pharmaceutical company in 3 places, with a total R&D expenditure of more than 20 billion yuan in the past 4 years; 6 companies, including Nuohezhiyuan, Nanowei Technology, and Jiahe Meikang, are expected to increase their net profit in 2021.
-
Six key words in the new stage of centralized procurement!
Time of Update: 2022-03-09
At the beginning of the new year, centralized procurement with volume is still an important starting point for the new medical reform, especially the "three medical linkage" reform with medical insur
-
Centralized hanging network, inter-provincial joint procurement, centralized procurement of traditional Chinese medicine formula granules is approaching!
Time of Update: 2022-03-09
According to the industry, since proprietary Chinese medicines have been included in volume procurement, the profit margins of the entire proprietary medicines have been greatly reduced, and most of the traditional Chinese medicines are covered by medical insurance reimbursement, resulting in a large number of medicines that were originally used for clinical promotion The representative turned to high-end Chinese herbal decoction pieces and formula granules .
-
Fujian announces the third batch of medical insurance key monitoring drugs and the list of key drugs
Time of Update: 2022-03-09
24), with the approval of the Provincial Medical Insurance Bureau, the "Third Batch of Medical Insurance Key Monitoring Drugs List" and the "Third Batch of Medical Insurance Focused Drug List" to be announced .
-
The three major varieties are out, and the top 10 best-selling drugs in 2022 will undergo great changes!
Time of Update: 2022-03-09
The biological targeting agent Dabitux may rank among the top 10 best-selling drugs in the world for the first time this year with a gratifying sales growth rate, while the anticoagulants Xarelto/Xarelto (rivaroxaban) and small molecules, which were at the bottom last year The BTK inhibitor Yike/Imbruvica (ibrutinib) and the ophthalmic biologic drug Aliya/Eylea (aflibercept), which are about to be impacted by biosimilars, were tragically eliminated .
-
Annual performance PK of multinational pharmaceutical companies!
Time of Update: 2022-03-09
Pfizer: New crown vaccine + oral drugs drive performance soaring Pfizer CEO Albert Bourla said that Pfizer’s sales in 2021 are expected to exceed $80 billion, the highest annual figure ever .
-
Stock price dives, R&D burns money, biopharmaceutical companies move forward tenaciously in 2021
Time of Update: 2022-03-08
Strong research and development strength is more favored by capital Wind data shows that from 2018 to 2020, A-share biopharmaceutical companies invested an average of 296 million yuan in research and development each year, much higher than the 146 million yuan of the entire pharmaceutical industry .
-
Guangxi promotes "going out" of traditional Chinese medicine and builds a joint laboratory with ASEAN
Time of Update: 2022-03-08
Guangxi Zhuang Autonomous Region Traditional Chinese Medicine Administration introduced on the 7th that during the "14th Five-Year Plan" period, Guangxi will implement the open cooperation project of traditional Chinese medicine Zhuang Yao medicine, promote the construction of Guangxi-ASEAN traditional medicine research and development center, and cooperate with ASEAN countries to build a joint laboratory .
-
A blockbuster medical law will go into effect, affecting doctors across the country
Time of Update: 2022-03-08
At the meeting, Xu Yucai, a well-known medical reform expert, explained the multi-point practice policy of doctors in the era of physician law for more than a thousand guests from all over the country .
![9-[3-Chloro-5-(phenanthren-9-yl)phenyl]phenanthrene / 1369431-34-4](https://file.echemi.com/fileManage/upload/goodpicture/20241028/9-3-chloro-5-phenanthren-9-ylphenylphenanthrene-1369431-34-4_b20241028151130118.jpg)
